Health economic issues in the treatment of drug-resistant serious Gram-positive infections.
Escalating health care costs have stimulated a paradigm change in the way health care is delivered, reimbursed, and evaluated. Reducing the length of hospital stay and controlling the cost of new technologies and therapies are major factors driving health care decisions. Economic evaluations have had variable success in the decision-making process, partly due to the overall quality, interpretation, and reporting of published analyses. Compared with other Gram-positive pathogens, the economic impact of methicillin-resistant Staphylococcus aureus (MRSA) infections remains the most studied. MRSA infections clearly represent a significant clinical and fiscal burden and future studies analyzing cost-effective strategies that encompass their prevention and optimal management would be beneficial. These studies would need to be carefully designed with clear objectives and explicit perspectives at the onset. Use of an appropriate reference group is key in the design process to measure the true impact of MRSA infections. Health-economic outcome data of the impact of linezolid compared with glycopeptides remain the most robust data available in this therapeutic area.